Instil Bio, Inc. TIL
6.86 USD +0.39 (+6.03%)
Nov 10, 2026, 9:31 AM EST
6.42 Day range 6.86
5.56 52-week range 16.00
- YTD
- -37.64%
- 1 year
- -53.68%
News
benzinga.com Instil Bio Q2 Adj. EPS $(0.45) Misses $(0.43) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.43) by 4.65 percent. This is a 84.37 percent increase over losses of $(2.88)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For May 15, 2026 - benzinga.com Earnings Scheduled For March 27, 2026
benzinga.com Instil Bio Q4 Adj. EPS $(0.97) Beats $(2.03) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(2.03) by 52.15 percent. This is a 10.19 percent increase over losses of $(1.08)…
benzinga.com Dow Jumps Over 400 Points; US Services Activity Falls In December 
benzinga.com Instil Bio Pulls Plug On Lead Drug Development Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new questions about its pipeline and next steps.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com US Stocks Mixed; Nasdaq Gains Over 50 Points - benzinga.com Instil Bio Q3 Adj. EPS $(1.75) Beats $(2.35) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.75) per share which beat the analyst consensus estimate of $(2.35) by 25.69 percent. This is a 31.37 percent increase over losses of $(2.55)…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
benzinga.com Instil Bio Says ImmuneOnco Biopharma Presents Preliminary Efficacy And Safety Data Of '2510 As Monotherapy In Phase 1 Study Of Patients In China With Previously Treated Sq-NSCLC At 2025 WCLC ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scoresDifferentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC…- benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com JMP Securities Reiterates Market Perform on Instil Bioto Market Perform JMP Securities analyst Reni Benjamin reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Market Perform.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Instil Bio, Lowers Price Target to $105 HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and lowers the price target from $110 to $105.
- benzinga.com Instil Bio, ImmuneOnco Advance Lung Cancer Drug '2510 With New Trials in China and US Plans Ahead Instil Bio, Inc. (NASDAQ:TIL, ", Instil", ))) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, "ImmuneOnco"), today announced clinical trial updates of ‘2510 and NSCLC clinical…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket 
benzinga.com Instil Bio Q1 Adj. EPS $(1.32) Beats $(2.59) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(2.59) by 49.03 percent. This is a 44.77 percent increase over losses of $(2.39)…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $110 Price Target HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $110 price target.
benzinga.com Instil Bio Q4 2024 GAAP EPS $(1.82) Beats $(3.22) Estimate, Instil Had $115.1M In Total Cash, Cash Equivalents, Restricted Cash And Marketable Securities, That Is Expected To Fund Its Current Operating Plan Beyond 2026 Instil Bio (NASDAQ:TIL) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(3.22) by 43.48 percent. This is a 8.54 percent increase over losses of $(1.99)…- benzinga.com JMP Securities Reiterates Market Perform on Instil Bioto Market Perform JMP Securities analyst Chris Muller reiterates Instil Bio (NASDAQ:TIL) from Market Perform to Market Perform.
- benzinga.com Instil Bio Announces Clinical Progress In China For IMM2510/SYN-2510, A Clinical-Stage PD-L1xVEGF Bispecific Antibody ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China.
benzinga.com Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.- benzinga.com Jefferies Upgrades Instil Bio to Buy, Raises Price Target to $52 Jefferies analyst Kelly Shi upgrades Instil Bio (NASDAQ:TIL) from Hold to Buy and raises the price target from $11 to $52.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $110 Price Target HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $110 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Instil Bio, Lowers Price Target to $110 HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and lowers the price target from $120 to $110.
- benzinga.com Instil Bio Q2 2024 GAAP EPS $(2.29) Beats $(2.85) Estimate Instil Bio (NASDAQ:TIL) reported quarterly losses of $(2.29) per share which beat the analyst consensus estimate of $(2.85) by 19.65 percent.
- benzinga.com JMP Securities Initiates Coverage On Instil Bio with Market Perform Rating JMP Securities analyst Reni Benjamin initiates coverage on Instil Bio (NASDAQ:TIL) with a Market Perform rating.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- benzinga.com Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $120 price target.- benzinga.com HC Wainwright & Co. Maintains Buy on Instil Bio, Raises Price Target to $120 HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and raises the price target from $40 to $120.
- benzinga.com Crude Oil Surges Over 1%; Instil Bio Shares Plunge
- benzinga.com Baird Reiterates Outperform on Instil Bio, Maintains $180 Price Target Baird analyst Jack Allen reiterates Instil Bio (NASDAQ:TIL) with a Outperform and maintains $180 price target.
- benzinga.com iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- benzinga.com Instil Bio Announced Global Registrational Strategy For PD-L1xVEGF Bispecific Antibody SYN-2510/IMM2510 In Combination With Chemotherapy In Front-line Non-small Cell Lung Cancer And In Front-line Triple-negative Breast Cancer Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC).Global registrational strategy in first-line triple-negative breast cancer (TNBC).Initiation…
- benzinga.com Baird Maintains Outperform on Instil Bio, Raises Price Target to $180 Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and raises the price target from $32 to $180.
- benzinga.com Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
- benzinga.com HC Wainwright & Co. Maintains Buy on Instil Bio, Raises Price Target to $40 HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and raises the price target from $25 to $40.
- benzinga.com ImmuneOnco Biopharmaceuticals Has Received A Near-Term Payment Of $5M From Instil Bio's SynBioTx, Bringing The Total Received Under Their License And Collaboration Agreement To $15M, With Potential Future Payments Up To $35M Expected https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0911/2024091100005.pdf
- benzinga.com HC Wainwright & Co. Maintains Buy on Instil Bio, Raises Price Target to $25 HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy and raises the price target from $18 to $25.